North China Pharmaceutical (SHA:600812) agreed to receive financial services from Jizhong Energy Group Finance for three years, according to a Wednesday disclosure on the Shanghai bourse.
The financial services will include deposit, settlement, credit, intermediary, and cash pooling management services.
Under the deal, the Chinese pharmaceutical company's daily deposits will not exceed 1 billion yuan, while annual credit should be at least 1 billion yuan.
North China Pharmaceutical's shares slipped over 1% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。